CYB 003
Alternative Names: CYB-003; Deuterated psilocin - Cybin; Deuterated-Psilocin - CybinLatest Information Update: 02 Dec 2025
At a glance
- Originator Cybin
- Class Antidepressants; Antipsychotics; Behavioural disorder therapies; Drug withdrawal therapies; Small molecules; Tryptamines
- Mechanism of Action Serotonin 5-HT2A receptor agonists
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Major depressive disorder
- Discontinued Alcoholism; Psychiatric disorders
Most Recent Events
- 30 Nov 2025 Cybin initiates a phase III EMBRACE trial in Major Depressive Disorder (Adjunctive treatment) in the USA (PO) (NCT06793397)
- 24 Nov 2025 Cybin has been granted approval to initiate phase III EMBRACE trial in the United States, Australia, Ireland, Poland, Greece, and the United Kingdom
- 26 Aug 2025 TGA approves Clinical Trial Notification application for the phase III EMBRACE trial in Major depressive disorder (Adjunctive treatment) in Australia